251 related articles for article (PubMed ID: 23166678)
1. Somatic mutations of PIK3R1 promote gliomagenesis.
Quayle SN; Lee JY; Cheung LW; Ding L; Wiedemeyer R; Dewan RW; Huang-Hobbs E; Zhuang L; Wilson RK; Ligon KL; Mills GB; Cantley LC; Chin L
PLoS One; 2012; 7(11):e49466. PubMed ID: 23166678
[TBL] [Abstract][Full Text] [Related]
2. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer.
Urick ME; Rudd ML; Godwin AK; Sgroi D; Merino M; Bell DW
Cancer Res; 2011 Jun; 71(12):4061-7. PubMed ID: 21478295
[TBL] [Abstract][Full Text] [Related]
3. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
McNeill RS; Stroobant EE; Smithberger E; Canoutas DA; Butler MK; Shelton AK; Patel SD; Limas JC; Skinner KR; Bash RE; Schmid RS; Miller CR
PLoS One; 2018; 13(7):e0200014. PubMed ID: 29975751
[TBL] [Abstract][Full Text] [Related]
5. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
[TBL] [Abstract][Full Text] [Related]
6. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
[TBL] [Abstract][Full Text] [Related]
7. Cooperative p16 and p21 action protects female astrocytes from transformation.
Kfoury N; Sun T; Yu K; Rockwell N; Tinkum KL; Qi Z; Warrington NM; McDonald P; Roy A; Weir SJ; Mohila CA; Deneen B; Rubin JB
Acta Neuropathol Commun; 2018 Feb; 6(1):12. PubMed ID: 29458417
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.
Weber GL; Parat MO; Binder ZA; Gallia GL; Riggins GJ
Oncotarget; 2011 Nov; 2(11):833-49. PubMed ID: 22064833
[TBL] [Abstract][Full Text] [Related]
11. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
[TBL] [Abstract][Full Text] [Related]
13. The Role of PIK3R1 in Metabolic Function and Insulin Sensitivity.
Tsay A; Wang JC
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628845
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
[TBL] [Abstract][Full Text] [Related]
15. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
16. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt.
Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC
Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767
[TBL] [Abstract][Full Text] [Related]
17. Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.
Goodwin CB; Yang Z; Yin F; Yu M; Chan RJ
Haematologica; 2012 Jul; 97(7):1042-7. PubMed ID: 22315502
[TBL] [Abstract][Full Text] [Related]
18. Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Lee JH; Lee JE; Kahng JY; Kim SH; Park JS; Yoon SJ; Um JY; Kim WK; Lee JK; Park J; Kim EH; Lee JH; Lee JH; Chung WS; Ju YS; Park SH; Chang JH; Kang SG; Lee JH
Nature; 2018 Aug; 560(7717):243-247. PubMed ID: 30069053
[TBL] [Abstract][Full Text] [Related]
19. Somatic PIK3R1 variation as a cause of vascular malformations and overgrowth.
Cottrell CE; Bender NR; Zimmermann MT; Heusel JW; Corliss M; Evenson MJ; Magrini V; Corsmeier DJ; Avenarius M; Dudley JN; Johnston JJ; Lindhurst MJ; Vigh-Conrad K; Davies OMT; Coughlin CC; Frieden IJ; Tollefson M; Zaenglein AL; Ciliberto H; Tosi LL; Semple RK; Biesecker LG; Drolet BA
Genet Med; 2021 Oct; 23(10):1882-1888. PubMed ID: 34040190
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
